These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17579193)

  • 1. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.
    Mueller A; Kiesewetter F; Binder H; Beckmann MW; Dittrich R
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3470-5. PubMed ID: 17579193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals.
    Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R
    J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.
    Jacobeit JW; Gooren LJ; Schulte HM
    J Sex Med; 2007 Sep; 4(5):1479-84. PubMed ID: 17635694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
    Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
    J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
    Kamischke A; Heuermann T; Krüger K; von Eckardstein S; Schellschmidt I; Rübig A; Nieschlag E
    J Clin Endocrinol Metab; 2002 Feb; 87(2):530-9. PubMed ID: 11836281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.
    Jacobeit JW; Gooren LJ; Schulte HM
    Eur J Endocrinol; 2009 Nov; 161(5):795-8. PubMed ID: 19749027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
    Gooren LJ; Giltay EJ; Bunck MC
    J Clin Endocrinol Metab; 2008 Jan; 93(1):19-25. PubMed ID: 17986639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females.
    Gooren LJG; Giltay EJ
    J Sex Med; 2008 Apr; 5(4):765-776. PubMed ID: 17971101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of three different testosterone formulations in female-to-male transsexual persons.
    Pelusi C; Costantino A; Martelli V; Lambertini M; Bazzocchi A; Ponti F; Battista G; Venturoli S; Meriggiola MC
    J Sex Med; 2014 Dec; 11(12):3002-11. PubMed ID: 25250780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
    Asscheman H; Giltay EJ; Megens JA; de Ronde WP; van Trotsenburg MA; Gooren LJ
    Eur J Endocrinol; 2011 Apr; 164(4):635-42. PubMed ID: 21266549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
    Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
    Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women.
    Spinder T; Spijkstra JJ; Gooren LJ; Hompes PG; van Kessel H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):200-7. PubMed ID: 2491861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.
    Meriggiola MC; Armillotta F; Costantino A; Altieri P; Saad F; Kalhorn T; Perrone AM; Ghi T; Pelusi C; Pelusi G
    J Sex Med; 2008 Oct; 5(10):2442-53. PubMed ID: 18624972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals.
    Elbers JM; Asscheman H; Seidell JC; Frölich M; Meinders AE; Gooren LJ
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3267-70. PubMed ID: 9329351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of androgen treatment on bone metabolism in female-to-male transsexuals.
    Lips P; van Kesteren PJ; Asscheman H; Gooren LJ
    J Bone Miner Res; 1996 Nov; 11(11):1769-73. PubMed ID: 8915785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
    Saad F; Gooren LJ; Haider A; Yassin A
    J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones.
    van Kesteren P; Lips P; Gooren LJ; Asscheman H; Megens J
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):347-54. PubMed ID: 9578826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3.
    Duschek EJ; Gooren LJ; Netelenbos C
    Maturitas; 2005 Jul; 51(3):286-93. PubMed ID: 15978972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.